Welcome to the Egetis Therapeutics webcast. My name is Nicklas Westerholm, CEO of Egetis Therapeutics.
Joining me today are Christian Sonesson, Vice President of Product Strategy and Development, Yilmaz Mahshid, Chief Financial Officer, as well as Karl Hård, Head of Investor Relations. This morning, we issued a press release announcing that Egetis Therapeutics has been granted a rolling new drug application, a so-called NDA review by the US FDA for Emcitate® for the treatment of MCT8 deficiency based on currently available clinical data. This is great news and the result of a very successful pre-NDA meeting we had with the FDA earlier this week. Following the granting of the Breakthrough Therapy designation in July.
We are strongly encouraged by the dialogue with the FDA on Emcitate, and we appreciate the agency's collaborative spirit as we work to deliver the first therapy to patients with MCT8 deficiency as efficiently as possible in the US.
The objective of the Pre-NDA meeting was to seek FDA advice and agreement on the overall content to support our NDA submission for Emcitate, with a special focus and emphasis on the clinical data package. We have now reached an agreement with the FDA that we can commence a rolling NDA submission in December 2025, targeting a complete NDA submission in early 2026 and the completion of the FDA review process in the third quarter of 2026, as we expect a priority review. This is, of course, a substantial step towards approval in the United States.
The Breakthrough Therapy designation was granted in July this year, based on the FDA's review of our independent analysis of the survival data from the international cohort study conducted by the Erasmus Medical Center, which we call the EMC Survival Study.
We will start the rolling submission in December with the non-clinical and quality modules of the NDA dossier, and complete the NDA with a clinical module in early 2026.
Importantly, the NDA for Emcitate® for the treatment of MCT8 deficiency will be based on currently available clinical data.
Considering that MCT8 deficiency is an ultra-rare disease, we have an unusually large and robust clinical data set from six different sources. This includes Triac Trial I with 46 patients, Triac Trial II with 22 patients, where data in the NDA will include long-term safety data up to four years of treatment in younger children. The ReTRIACt study involved 15 patients, the EMC Cohort Study included 67 patients, and the EMC Survival Study comprised over 600 patients, as well as the US Expanded Access Program, where we currently have around 30 patients. Importantly, the ongoing ReTRIACt study is no longer considered pivotal for the new drug application, which it was when the study was originally designed. The study will be closed as soon as possible, and no further patients will be added.
The FDA has recommended that the statistical analysis plan be revised. The so-called SAP for the trial will be revised. While I can't comment on any specific details about the ReTRIACt study or the SAP. What I can say is the revised SAP will reflect the fact that the ReTRIACt study is now a complementary study to the survival data and other clinical components in the NDA, rather than being the pivotal study. We estimate top-line results from the ReTRIACt study will be communicated during the fourth quarter of 2025. Data accrued to date will be included in the NDA. So in summary, we are very pleased with the agreement with the FDA, which provides a clear path to an NDA for Emcitate in the US, based on the currently available clinical data within the coming months. So with that, I would like to open up for questions. Operator. Please go ahead.